Treatment (mg/kg) | Body weight (BW)(g) | Heart weight (HW)(g) | Ratio (HW/BWx103) |
---|
Initial | Final | Â | Â |
---|
Control | 219.0 ± 0.577 | 250.3 ± 0.333b
| 0.501 ± 0.023 | 2.00 |
DOX | 221.3 ± 0.667 | 226.3 ± 0.661a
| 0.76 ± 0.021a
| 3.35 |
AHE alone | 220.3 ± 0.667 | 248.3 ± 0.671b
| 0.509 ± 0.01b
| 2.04 |
DOX + AHE (200) | 221.7 ± 0.882 | 232.2 ± 0.611a,b
| 0.651 ± 0.019a**b*c** | 2.80 |
DOX + AHE (400) | 220.3 ± 0.882 | 244.7 ± 0.882a,b,c
| 0.534 ± 0.017b
| 2.18 |
DOX + Sily | 222.0 ± 0.577 | 243.3 ± 0.333a,b
| 0.541 ± 0.018b
| 2.22 |
- Data expressed as mean ± SEM (n = 6)
-
asignificant difference of final body weight of group Vs. Control group at p < 0.0001
-
bsignificant difference of final body weight of group Vs. DOX-treated group at p < 0.0001
-
csignificant difference of final body weight of DOX + AHE (200 mg/kg) treated group Vs. DOX + AHE (400 mg/kg) treated group at p < 0.001
- *, **indicate significance at p < 0.05 and p < 0.001. Non-significant difference (p > 0.05) was recorded between control and AHE alone treated group in all parameters. (One way ANOVA followed by Tukey’s multiple comparison tests). Sily-Silymarin